Cargando…

Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy

OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Borges, Karin, Kaul, Neha, Germaine, Jack, Kwan, Patrick, O'Brien, Terence J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398112/
https://www.ncbi.nlm.nih.gov/pubmed/30868125
http://dx.doi.org/10.1002/epi4.12308
_version_ 1783399530500194304
author Borges, Karin
Kaul, Neha
Germaine, Jack
Kwan, Patrick
O'Brien, Terence J.
author_facet Borges, Karin
Kaul, Neha
Germaine, Jack
Kwan, Patrick
O'Brien, Terence J.
author_sort Borges, Karin
collection PubMed
description OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospective baseline period, people with drug‐resistant epilepsy were randomized in a double‐blind fashion to receive triheptanoin or MCTs. Treatment was titrated over 3 weeks to a maximum of 100 mL/d to be distributed over 3 meals and mixed into food, followed by 12‐week maintenance before tapering. The primary aims were to assess the following: (a) safety by comparing the number of intervention‐related adverse events with triheptanoin vs MCT treatment and (b) adherence, measured as a percentage of the prescribed treatment doses taken. RESULTS: Thirty‐four people were randomized (17 to MCT and 17 to triheptanoin). There were no differences regarding (a) the number of participants completing the study (11 vs 9 participants), (b) the time until withdrawal, (c) the total number of adverse events or those potentially related to treatment, (d) median doses of oils taken (59 vs 55 mL/d, P = 0.59), or (e) change in seizure frequency (54% vs 102%, P = 0.13). Please note that people with focal unaware seizures were underrepresented in the triheptanoin treatment arm (P = 0.04). The most common adverse events were gastrointestinal disturbances (47% and 62.5% of participants). Five people taking on average 0.73 mL/kg body weight MCTs (0.64 mL/kg median) and one person taking 0.59 mL/kg triheptanoin showed >50% reduction in seizure frequency, specifically focal unaware seizures. SIGNIFICANCE: Add‐on treatment with MCTs or triheptanoin was feasible, safe, and tolerated for 12 weeks in two‐thirds of people with treatment‐resistant epilepsy. Our results indicate a protective effect of MCTs on focal unaware seizures. This warrants further study.
format Online
Article
Text
id pubmed-6398112
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63981122019-03-13 Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy Borges, Karin Kaul, Neha Germaine, Jack Kwan, Patrick O'Brien, Terence J. Epilepsia Open Full‐length Original Research OBJECTIVE: To investigate the feasibility, safety, and tolerability of add‐on treatment of the triglycerides of heptanoate (triheptanoin) vs the triglycerides of octanoate and decanoate (medium chain triglycerides [MCTs]) in adults with treatment‐refractory epilepsy. METHODS: After an 8‐week prospective baseline period, people with drug‐resistant epilepsy were randomized in a double‐blind fashion to receive triheptanoin or MCTs. Treatment was titrated over 3 weeks to a maximum of 100 mL/d to be distributed over 3 meals and mixed into food, followed by 12‐week maintenance before tapering. The primary aims were to assess the following: (a) safety by comparing the number of intervention‐related adverse events with triheptanoin vs MCT treatment and (b) adherence, measured as a percentage of the prescribed treatment doses taken. RESULTS: Thirty‐four people were randomized (17 to MCT and 17 to triheptanoin). There were no differences regarding (a) the number of participants completing the study (11 vs 9 participants), (b) the time until withdrawal, (c) the total number of adverse events or those potentially related to treatment, (d) median doses of oils taken (59 vs 55 mL/d, P = 0.59), or (e) change in seizure frequency (54% vs 102%, P = 0.13). Please note that people with focal unaware seizures were underrepresented in the triheptanoin treatment arm (P = 0.04). The most common adverse events were gastrointestinal disturbances (47% and 62.5% of participants). Five people taking on average 0.73 mL/kg body weight MCTs (0.64 mL/kg median) and one person taking 0.59 mL/kg triheptanoin showed >50% reduction in seizure frequency, specifically focal unaware seizures. SIGNIFICANCE: Add‐on treatment with MCTs or triheptanoin was feasible, safe, and tolerated for 12 weeks in two‐thirds of people with treatment‐resistant epilepsy. Our results indicate a protective effect of MCTs on focal unaware seizures. This warrants further study. John Wiley and Sons Inc. 2019-02-22 /pmc/articles/PMC6398112/ /pubmed/30868125 http://dx.doi.org/10.1002/epi4.12308 Text en © 2019 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Full‐length Original Research
Borges, Karin
Kaul, Neha
Germaine, Jack
Kwan, Patrick
O'Brien, Terence J.
Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
title Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
title_full Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
title_fullStr Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
title_full_unstemmed Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
title_short Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
title_sort randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
topic Full‐length Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398112/
https://www.ncbi.nlm.nih.gov/pubmed/30868125
http://dx.doi.org/10.1002/epi4.12308
work_keys_str_mv AT borgeskarin randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy
AT kaulneha randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy
AT germainejack randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy
AT kwanpatrick randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy
AT obrienterencej randomizedtrialofaddontriheptanoinvsmediumchaintriglyceridesinadultswithrefractoryepilepsy